Abstract
Background: AT1R (Angiotensin II type 1 receptor) is the main component of RAS (renin-angiotensin system) system, which activates when ANG II (angiotensin II) binds to it. AT1R helps in maintaining osmotic homeostasis and blood pressure regulation. A huge number of polymorphism are associated with AT1R and few of them were studied and found to be associated with the diseases and drug efficacy. Although it is a very important receptor most of the polymorphisms (SNPs) were not studied for their implications in diseases. A huge number of polymorphisms are reported in the databases for AT1R, which provide an avenue to explore these polymorphisms for their implications in protein structure, function and drug efficacy.
Methods: In the current study, all the SNPs (10234) reported in NCBI were analyzed and SNPs that were important in protein structure and drug interactions were identified. Structures of these polymorphic forms were modeled and in silico drug interaction studies were carried out.
Results: The result of the interaction studies with polymorphism was in correlation with the reported case. Two SNP mutated structures of AT1R i.e. rs780860717 (G288T), rs868647200 (A182C) show considerably less binding affinities in the case of all angiotensin receptor blockers (ARBs). As a result, these polymorphisms may show less efficacy toward these ARBs. The other mutated structures rs12721226 (A163G), rs749234826 (A292G), rs775810028 (A87G), show increased binding affinities in case of Eprosartan and most of the mutated structures shows increased binding affinity toward Telmisartan than the wild type AT1R. Similarly, these polymorphisms may show increased efficacy in the case of these two ARBs.
Conclusion: The outcome of the study will help in designing better drugs in the near future with broader spectrum. Furthermore, in vitro and in vivo studies can be designed according to the current results.
Keywords: Renin-angiotensin system, angiotensin II, angiotensin II type 1 receptor, single-nucleotide polymorphisms, angiotensin receptor blockers, drug.
Graphical Abstract
14